Stock Traders Purchase Large Volume of Solventum Call Options (NYSE:SOLV)

Solventum Corporation (NYSE:SOLV) was the target of unusually large options trading on Tuesday. Traders purchased 3,171 call options on the stock. This represents an increase of 1,153% compared to the typical daily volume of 253 call options.

Solventum Price Performance

Shares of NYSE SOLV opened at $86.26 on Wednesday. The firm has a market cap of $14.94 billion, a P/E ratio of 10.57, a PEG ratio of 1.24 and a beta of 0.66. Solventum has a twelve month low of $62.38 and a twelve month high of $88.20. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The company has a 50 day moving average of $77.78 and a 200 day moving average of $74.17.

Solventum (NYSE:SOLV) last issued its earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.35 by $0.13. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company’s revenue was down 3.0% compared to the same quarter last year. During the same period last year, the business posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, research analysts expect that Solventum will post 6.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SOLV has been the subject of several recent research reports. UBS Group upgraded Solventum from a “neutral” rating to a “buy” rating and set a $95.00 price objective for the company in a research report on Tuesday. Weiss Ratings raised shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 17th. BMO Capital Markets started coverage on shares of Solventum in a report on Wednesday, July 8th. They set a “market perform” rating and a $81.00 price target for the company. Piper Sandler dropped their price target on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Finally, Wedbush initiated coverage on shares of Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $86.00.

Institutional Investors Weigh In On Solventum

Several large investors have recently bought and sold shares of SOLV. Assetmark Inc. lifted its stake in Solventum by 21.4% during the 4th quarter. Assetmark Inc. now owns 725 shares of the company’s stock valued at $57,000 after acquiring an additional 128 shares during the period. BOKF NA grew its stake in shares of Solventum by 6.9% in the third quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after acquiring an additional 141 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of Solventum by 23.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 744 shares of the company’s stock worth $60,000 after acquiring an additional 142 shares during the period. NewEdge Advisors LLC raised its holdings in shares of Solventum by 2.2% during the first quarter. NewEdge Advisors LLC now owns 6,707 shares of the company’s stock valued at $438,000 after purchasing an additional 144 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators raised its holdings in shares of Solventum by 39.5% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 516 shares of the company’s stock valued at $41,000 after purchasing an additional 146 shares during the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.